综述:SARS-CoV-2 刺突蛋白:结构、病毒进入机制及变体 《Nature Reviews Microbiology》:SARS-CoV-2 spike protein: structure, viral entry and variants 编辑推荐: 这篇综述聚焦 SARS-CoV-2 刺突蛋白(S 蛋白),阐述其结构与功能、病毒入侵细胞的分子机制,分析新变体的出现,探讨这些对开发基于 S 蛋白的治疗和疫苗...
Rapid progress in the structural biology of SARS-CoV-2 S protein has been made since the early stage of the pandemic, advancing our knowledge on the viral entry process considerably. In this review, we summarize our latest understanding of the structure of the SARS-CoV-2 S protein and ...
SARS-CoV-2 spike (S) protein is a key target for eliciting neutralizing antibodies.aSchematic structures of SARS-CoV-2 virion and its S protein. M, membrane; E, envelope; N, nucleocapsid. Viral RNA is located inside the virion. NTD, N-terminal domain; RBD, receptor-binding domain; FP, ...
1. Hoffmann M. et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16. 2. Walls A.C. et al., 2020. Structure, function, and anti...
A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934–941 (2020). Toelzer, C. et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science eabd3255 (2020). Henderson, R. et al. Controlling the SARS-CoV-2 ...
SARS-CoV-2 spike protein: structure, viral entry and variants Explore related subjects Discover the latest articles and news from researchers in related subjects, suggested using machine learning. Carrier proteins Protein Structure Protein vaccines ...
一个国际研究小组在《Nature Communications》上发表的新研究发现,COVID-19患者可能有几种不同的SARS-CoV-2变异,它们隐藏在身体不同部位的免疫系统之外。该研究的作者说,这可能会使感染者通过自身抗体或治疗性抗体治疗,从体内彻底清除病毒变得更加困难。
先前的研究也揭示了位于 SARS-CoV-2 RBD 上的保守表位的存在。因此,去鉴定和靶向 SARS-CoV-2 变体中高度保守的表位看来是很可行的,对于设计广泛中和抗体和疫苗可能很重要。 在这篇文章中,作者团队设计了一种双特异性抗体,而且可以通过吸入式有效地输送到肺部,并在 SARS-CoV-2 感染的小鼠模型中表现出优异的疗效...
SARS-CoV-2表面含有刺状糖蛋白,这是当前疫苗开发的主要目标,因为针对这种蛋白的抗体可以中和感染。公司和学术机构已开发出基于S糖蛋白及其抗原域和表位的疫苗,这些抗原域和表位已被证明能有效产生中和抗体。然而,新的SARS-CoV-2变种的出...
SARS-CoV-2 trimeric prefusion spike protein can be produced and stored stably, it has a significant impact on COVID-19 vaccine development and basic research. Sino Biological has developed serval SARS-CoV-2 Prefusion Trimeric Spike Variant Proteins.